However, when generating or expanding tumor-reactive T cells for CAR T cell, TCR-transduced T cell or TIL therapy, PBMCs or total CD3+ T cells are mostly used instead of purified CD8+ T cells [2, 37–40, 44]. The gene discussed is CD8A; the disease is neoplasm.